Zheyuan Tech Secures RMB 100 Million Series A1 Financing to Advance AI-Driven Drug Discovery Platform

News on December 16: PHIL RIVERS TECHNOLOGY Co., Ltd. ("PHIL RIVERS") announced the completion of its A1 round of financing worth hundreds of millions. This round of financing was led by CAS Investment, with participation from Zeyuan Fund and ChemPartner.

PHIL RIVERS TECHNOLOGY Co., Ltd.'s current funding round will mainly be used for the continuous advancement of core drug pipelines, global patent layout of high-value innovative IP, and the upgrade of the computational medicine platform, further unleashing the company's capacity as a "drug IP innovation factory" to drive the transformation of the R&D paradigm in the biopharmaceutical industry.

PHIL RIVERS TECHNOLOGY Co., Ltd. is a platform company that empowers pharmaceutical innovation through artificial intelligence technology. The company focuses on "AI4S + disease"-driven drug development, with digital twin technology for life functions at its core, creating a computational medicine platform. The company is committed to building a "digital testing ground for drugs," systematically discovering new targets, identifying drugs, simulating clinical trials, and expanding new indications for drugs, introducing a new paradigm for pharmaceutical R&D. The company already owns multiple high-value IPs, including new targets and new drugs.